Prometheus Biosciences, Inc., (RXDX): Price and Financial Metrics

Prometheus Biosciences, Inc., (RXDX): $41.54

-0.60 (-1.42%)

POWR Rating

Component Grades













Add RXDX to Watchlist
Sign Up

Industry: Biotech



in industry

RXDX Stock Summary

  • With a one year PEG ratio of 0.53, PROMETHEUS BIOSCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.94% of US stocks.
  • RXDX's price/sales ratio is 245.72; that's higher than the P/S ratio of 98.71% of US stocks.
  • Revenue growth over the past 12 months for PROMETHEUS BIOSCIENCES INC comes in at 129.88%, a number that bests 93.65% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RXDX, based on their financial statements, market capitalization, and price volatility, are SELB, PLRX, BPMC, RAPT, and MTEM.
  • Visit RXDX's SEC page to see the company's official filings. To visit the company's web site, go to

RXDX Valuation Summary

  • RXDX's price/sales ratio is 260.8; this is 12940% higher than that of the median Healthcare stock.
  • Over the past 21 months, RXDX's EV/EBIT ratio has gone up 11.2.

Below are key valuation metrics over time for RXDX.

Stock Date P/S P/B P/E EV/EBIT
RXDX 2022-11-25 260.8 8.1 -14.1 -13.7
RXDX 2022-11-23 251.4 7.8 -13.6 -13.2
RXDX 2022-11-22 268.9 8.3 -14.6 -14.2
RXDX 2022-11-21 265.1 8.2 -14.3 -14.0
RXDX 2022-11-18 265.1 8.2 -14.3 -14.0
RXDX 2022-11-17 256.6 7.9 -13.9 -13.5

RXDX Price Target

For more insight on analysts targets of RXDX, see our RXDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $34.67 Average Broker Recommendation 1.12 (Strong Buy)

RXDX Stock Price Chart Interactive Chart >

Price chart for RXDX

RXDX Price/Volume Stats

Current price $41.54 52-week high $63.13
Prev. close $42.14 52-week low $21.50
Day low $41.10 Volume 385,200
Day high $43.76 Avg. volume 443,089
50-day MA $50.65 Dividend yield N/A
200-day MA $40.92 Market Cap 1.74B

Prometheus Biosciences, Inc., (RXDX) Company Bio

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.

RXDX Latest News Stream

Event/Time News Detail
Loading, please wait...

RXDX Latest Social Stream

Loading social stream, please wait...

View Full RXDX Social Stream

Latest RXDX News From Around the Web

Below are the latest news stories about PROMETHEUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RXDX as an investment opportunity.

Prometheus Biosciences Third Quarter 2022 Earnings: Beats Expectations

Prometheus Biosciences ( NASDAQ:RXDX ) Third Quarter 2022 Results Key Financial Results Net loss: US$37.3m (loss...

Yahoo | November 12, 2022

Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position provides runway into mid-2024 - SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic prod

Yahoo | November 9, 2022

Prometheus Biosciences to Participate at November Healthcare Conferences

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will conduct fireside chats at the following healthcare conferences: Credit Suisse Annual Healthcare ConferenceDate: Tuesday, November 8, 2022

Yahoo | November 1, 2022

Prometheus Biosciences (NASDAQ:RXDX) pulls back 15% this week, but still delivers shareholders splendid 103% return over 1 year

It's been a soft week for Prometheus Biosciences, Inc. ( NASDAQ:RXDX ) shares, which are down 15%. But that doesn't...

Yahoo | October 12, 2022

Read More 'RXDX' Stories Here

RXDX Price Returns

1-mo -20.91%
3-mo -26.28%
6-mo 49.37%
1-year 39.87%
3-year N/A
5-year N/A
YTD 5.06%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9176 seconds.